BRAINSWAY LTD/S (NASDAQ:BWAY) Upgraded by Zacks Investment Research to “Buy”
Posted by Amelie Mason on Jun 17th, 2020
BRAINSWAY LTD/S logoZacks Investment Research upgraded shares of BRAINSWAY LTD/S (NASDAQ:BWAY) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. The firm currently has $7.75 target price on the stock.
According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “
BWAY has been the subject of several other research reports. ValuEngine upgraded BRAINSWAY LTD/S from a hold rating to a buy rating in a report on Friday, March 6th. Cantor Fitzgerald decreased their price objective on BRAINSWAY LTD/S from $17.00 to $13.00 and set an overweight rating for the company in a report on Tuesday, March 24th. Finally, Raymond James decreased their price objective on BRAINSWAY LTD/S from $13.00 to $9.00 and set an outperform rating for the company in a report on Tuesday, March 24th.
BWAY stock traded up $0.15 during trading hours on Tuesday, reaching $7.07. 1,615 shares of the stock were exchanged, compared to its average volume of 3,082. The firm’s 50-day moving average is $7.87 and its 200-day moving average is $9.26. The company has a market cap of $75.21 million, a price-to-earnings ratio of -14.14 and a beta of 0.90. BRAINSWAY LTD/S has a 12 month low of $5.10 and a 12 month high of $12.53.
BRAINSWAY LTD/S (NASDAQ:BWAY) last released its earnings results on Monday, March 23rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.02. The firm had revenue of $6.29 million during the quarter, compared to analysts’ expectations of $6.25 million. BRAINSWAY LTD/S had a negative return on equity of 48.90% and a negative net margin of 44.71%. Equities analysts expect that BRAINSWAY LTD/S will post -0.48 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James & Associates grew its holdings in BRAINSWAY LTD/S by 54.1% during the fourth quarter. Raymond James & Associates now owns 28,500 shares of the company’s stock worth $278,000 after purchasing an additional 10,000 shares during the period. Phoenix Holdings Ltd. grew its holdings in BRAINSWAY LTD/S by 3.8% during the first quarter. Phoenix Holdings Ltd. now owns 321,895 shares of the company’s stock worth $2,496,000 after purchasing an additional 11,895 shares during the period. Finally, Cowen AND Company LLC bought a new position in BRAINSWAY LTD/S during the first quarter worth about $2,734,000. Institutional investors own 17.37% of the company’s stock.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.